Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.75
Bid: 2.60
Ask: 2.90
Change: 0.15 (5.77%)
Spread: 0.30 (11.538%)
Open: 2.80
High: 2.95
Low: 2.75
Prev. Close: 2.60
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Amigo heads to vote; UniVision court date pushed back

Tue, 15th Mar 2022 17:18

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Amigo Holdings PLC- guarantor loans provider - Says high court grants order that schemes of arrangement can proceed to a creditor vote. "The road ahead is not easy, but we are on the right track and today's court decision is another step forward," says Chief Executive Gary Jennison. Creditors' meeting to be held in May and, if they vote for the scheme, the court sanction hearing is expected to be held later that month. Scheme is being proposed to settle claims following probes from UK regulators into mis-sold loans and the way that Amigo dealt with customer complaints. Jennison says "significant hurdles remain". Adds: "We are pleased that the court has agreed that the schemes can proceed to a creditor vote. The financial offer has been significantly improved and we will be doing everything we can to encourage creditor participation."

----------

Digital 9 Infrastructure PLC - London-based digital infrastructure investor - Signs new GBP300 million revolving credit facility with an international syndicate of four banks including the Royal Bank of Scotland International Ltd, DNB Ltd, Royal Bank of Canada and Banco Santander. "Triple Point Investment Management LLP, the group's investment manager, continues to identify attractive investment opportunities for the company's portfolio. The new RCF will provide the group with additional committed capital, to help finance the acquisition of further investments from its near-term pipeline. The investment manager remains focused on converting its pipeline of about GBP2 billion of potential assets," company says.

----------

Aptitude Software Group PLC - London-based finance transformation and automation software - Decides to further increase investment in product strategy in 2022 and 2023, though warns this is expected to "dampen short term profitability". "The board believes this accelerated strategic investment will create longer term sustainable value for the group and our shareholders," it says. Expects improving margins from 2024 and beyond. This comes alongside annual results for 2021, in which total revenue rises 3% to GBP59.3 million but pretax profit falls to GBP6.2 million from GBP8.1 million in 2020.

----------

Mobile Streams PLC - mobile content provider - Raises GBP1.2 million in placing priced at 0.30p per share. Funds to support company's growth and to create a new joint venture partnership with Gfinity PLC for Mobilegaming.com. "The company is working to agree the terms of the joint venture and expects to announce the conclusion of the agreement shortly," it says. Gfinity shares rise 6.2%.

----------

Smart Metering Systems PLC - Glasgow-based provider of end-to-end services in utility connections, smart metering and energy management - Pretax profit in 2021 slumps to GBP8.3 million from GBP195.0 million in 2020, which was attributed to a hefty gain from its I&C meter portfolio disposal the year prior. Revenue improves to GBP108.5 million from GBP103.0 million. Annual dividend upped to 27.5 pence from 25.0p. Chief Executive Tim Mortlock says: "Our contracted smart meter order pipeline remains solid and now more favourably weighted to larger, well-financed independent energy suppliers, and supported by the extension to our exclusivity agreement with Shell Energy Retail. We expect our installation rate to progressively increase throughout the coming year."

----------

UniVision Engineering Ltd - Hong Kong-based firm which installs closed circuit television surveillance systems - Court hearing for winding up petition adjourned until April 19, 2022. Hearing regards GBP565,280 alleged debt owed by company to sub-contractor T&P Solutions Ltd, formerly known as T&P Construction Co. Previously says: "The company intends to defend and oppose the petition. The company has separately been advised that it has a cross claim against T&P, inter alia, for breach of contract and non-performance and it intends to claim damages for the same."

----------

ValiRx PLC - cancer and women's health treatment developer - Says it is assessing options to acquire capabilities and infrastructure to create a "more efficient and effective" translational drug development service. Says revenue generated from providing pre-clinical development services would enable continued investment in advanced testing and analysis technology and support the progression of ValiRx in-house pipeline projects.

----------

Tlou Energy Ltd - power company focused on sub-Saharan Africa - Says contract for the construction of the transmission line to connect the Lesedi power project to Botswana's electricity grid has been signed. Botswana-based Zismo Engineering Pty Ltd has been engaged to construct the line, and expects to mobilise plant and equipment on site in the coming weeks.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
24 Jun 2014 09:23

DIRECTOR DEALINGS: ValiRx Directors Buy 5.3 Million Shares

Read more
10 Jun 2014 10:00

ValiRx Submits Application For VAL201 Cancer Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that it has submitted an application to the Medicines and Healthcare Products Regulatory Agency for a phase I/II extended clinical study, or trial, of VAL201 in people with cancer. VAL201 is ValiRx's leading anti-cancer therapeutic candidate.

Read more
10 Jun 2014 09:45

Tuesday broker round-up UPDATE

ASOS: Goldman Sachs reduces target price from 6250p to 5750p, while upgrading to strong buy. Avon Rubber: Investec lowers target price from 690p to 680p and downgrades from buy to add. BAE Systems: Investec downgrades from add to hold with a target price of 430p. BG Group: Exane downgrades to neu

Read more
15 May 2014 13:31

ValiRx Sees Progress On Cancer Drug Development From Joint Venture

LONDON (Alliance News) - ValiRx PLC said Thursday that it had seen promising progress on the development of its cancer treatment VAL401 towards Phase II trials since the formation of its joint venture with Tangent Reprofiling Ltd, ValiSeek. The joint venture was formed a month ago to progre

Read more
1 May 2014 10:15

ValiRx Granted Patent For Cancer Screening Biomarker In Japan

LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3. The biomarker was acquired by the company's subsidiary ValiFinn Oy in 2012. As a result, ValiRx now has patent protection on this biomarker i

Read more
8 Apr 2014 11:05

ValirX In Joint Venture With Tangent Reprofiling For Cancer Drug Development

LONDON (Alliance News) - ValiRx PLC Tuesday said it has established a risk-sharing joint venture with Tangent Reprofiling Ltd which will progress Tangent's VAL401 potential cancer drug through its remaining preclinical development and towards Phase II trials. ValirX said it has acquired a 6

Read more
1 Apr 2014 09:22

ValiRx Anti-Cancer Compound To Undergo Further Study

LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further stability and sterility study to allow for the acceleration towards a Phase 2 efficacy study. ValiRx said it had accepted the advice of the tea

Read more
19 Mar 2014 12:10

ValiRx Loss Widens As It Ups Investment In Clinical Trial Programme

LONDON (Alliance News) - Biotechnology company ValiRx PLC Wednesday posted a widened pretax loss in 2013 as revenue declined, and it upped investment in the clinical trial programme for its anti-cancer therapeutic VAL201. The company posted a pretax loss of GBP2.9 million, widened from GBP2

Read more
20 Feb 2014 11:10

ValiRx Biomarket Receives European Patent Approval

LONDON (Alliance News) - ValiRx PLC Thursday said a cancer screening test gene biomarker called NAV3, acquired by its subsidiary in 2012, has received patent approval from the European Patent Office. In a statement, ValiRx said the latest approval means it has biomarker patent protection in

Read more
31 Jan 2014 13:03

ValiRx Sells Shares In VolitionRx For USD601,578

LONDON (Alliance News) - ValirRx PLC Friday said it has sold its shareholding in VolitionRx to an unnamed firm for USD601,578 and will use the proceeds for the continuing clinical development of its anti-cancer therapeutics VAL101 and VAL201. The life science company had 510,811 shares in c

Read more
27 Dec 2013 08:27

ValiRx Raises GBP2.9 Million In Placing To Fund Oncology Work

Read more
28 Nov 2013 12:27

CORRECT: AIM IN BRIEF: Herstal Emerges As Favourite To Acquire Manroy

Read more
28 Nov 2013 08:22

AIM IN BRIEF: Beretta Emerges As Favourite To Acquire Manroy

Read more
15 Nov 2013 12:39

CORRECT: ValiRx Raises GBP1M Through Placing; Shares Fall Toward Placing Price

Read more
15 Nov 2013 12:37

UK WINNERS & LOSERS: IAG Dives Despite Raising Profit Guidance

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.